BPDCN: A Dermatologist's Perspective on Differential Diagnosis

Jesse Hirner

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Indy Hematology Review

H. Erba

Understanding the NPM1 Mutation in AML: Dr. Jekyll and Mr. Hyde

SOHO Brazil 2024

J. Lancet

Experts Discuss the Pathophysiology, Diagnosis, and Treatment of BPD…

MyCancerHaven

R. Vij, G. Murthy

Where I Use Azacitidine and Venetoclax in AML: Present and Future

SOHO Brazil 2024

J. Lancet

2024 Updates in AML

University of Colorado Division of Hematology

C. McMahon

Emerging Treatment Options for AML in 2024

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

A. Perl

Administration and Dosing of Tagraxofusp for BPDCN

Emanuele Angelucci

BPDCN: Current and Future Directions

Icahn School of Medicine at Mount Sinai

N. Pemmaraju

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

UChicago Medicine 12th International Clinical Cancer Genomics Conference

L. Banaszak

Integrating Targeted Therapies in AML

Icahn School of Medicine at Mount Sinai

H. Kantarjian

Immunotherapies in Acute Leukemias: 2024 Update

Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

C. Lai

Current Treatment Landscape in BPDCN

Cristina Papayannidis

ASCO® 2024 Summary: "Optimal Treatment Strategies for Younger Patien…

2024 ASCO® Annual Meeting Insights Hub

C. McMahon

Is Post-HSCT Maintenance the SOC for AML?

Rush University Medical Center

M. Levis

SOHO Italy 2023: How I Treat AML at MD Anderson Cancer Center

5th SOHO Italy Annual Conference

H. Kantarjian

AML: Current Treatment Landscape and Key Recent Updates

UChicago Medicine

A. Patel

EHA 2024 Insights: Real-World Data From R/R BPDCN Treated With Tagra…

Insights from 2024 EHA Annual Meeting

E. Angelucci

Importance of AML Maintenance Therapy

Gautam Borthakur